[29P-pm] Pathophysiology

[29P-pm482] Survey and Consideration for Tissue Distribution of Globally-Approved Oligonucleotide Therapeutics

○Mika Miyoshi^1,2, Kei Fukuhara^1,3, Naomi Tamura^1,4, Yutaka Niwayama^1,5, Yasufumi Fukano^1,6, Shunji Imai^1,7 (1. Japan Pharmaceutical Manufacturers Association, 2. Sanwa Kagaku Kenkyusho, 3. Pfizer R&D, 4. Shionogi, 5. Kyorin Pharmaceutical, 6. Nippon Boehringer Ingelheim, 7. Nippon Shinyaku)